Please login to the form below
Alcon
This page shows the latest Alcon news and features for those working in and with pharma, biotech and healthcare.
Takeda sells blockbuster-in-waiting Xiirda to Novartis for $5.3bn
eye care division Alcon earlier this year.
Latest news
-
Alcon spun off, leaner Novartis raises profit forecast
The Switzerland-headquartered firm has just spun off its eye care division Alcon, raising $4.7bn in the process, and helping it to create a leaner firm focused on medicines, and ... Novartis is off to a strong start in 2019 with the Mayzent launch,
-
Francis exits Sandoz, reigniting spinoff rumours
Novartis already have the spin-off of its eyecare division Alcon in the pipeline, with the business unit to be divested in the first half of this year.
-
Novartis aims for 10 blockbuster launches by 2020
The company also announced cuts to its manufacturing operations, and confirmed the spin off of eyecare division Alcon, which could raise as much as $35bn this year.
-
Novartis sells off part of Sandoz portfolio
from its eye-division Alcon, which it acquired back in 2010.
-
GSK: we won’t be splitting up any time soon
The decision is in contrast to firms such as Novartis (selling its eyecare divison Alcon) and Lilly, which just announced the spin-off its animal health division Elanco.
More from news
Approximately 17 fully matching, plus 52 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
To date it seems Sanofi is also considering a move. Meanwhile Novartis is reportedly considering a sale of its contact lens business which is part of the Alcon eye care division.
-
Pharma deals during April 2014
Remaining revenues will come from pharmaceuticals, eye care (Alcon) and generics (Sandoz) and of course its stake in GSK Consumer Health.
-
Healthcare industry apps
Developed by Alcon (a Novartis company) this comprehensive tool is designed to teach doctors how to make diagnoses using an ophthalmoscope.
-
Interview: Joseph Jimenez, Novartis
Our new eye-care business Alcon is also driving our growth, with net sales increasing six per cent in Q2.". ... Alcon is already delivering solid sales growth, with sales up six per cent on a proforma basis in the second quarter.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Agios appoints Celgene’s Jackie Fouse
Prior to her tenure at Celgene, Fouse worked for Alcon Laboratories, an ophthalmic pharmaceutical and medical device company.
-
Celgene’s president and COO to retire
Previously, Dr Fouse was chief financial officer of agribusiness and food company Bunge, and also brought executive leadership expertise from Alcon Laboratories and Nestlé.
-
Dr Robert Kim joins Apellis as chief medical officer
Meanwhile, at he served at GSK as VP of clinical ophthalmology, helping build its early stage clinical pipeline, and was VP and head of pharmaceutical product development at Novartis/Alcon.
-
Novartis makes trio of appointments to senior leadership team
Ball has been appointed as the new division head and chief executive officer of Alcon, replacing Jeff George, and is set to focus on its surgical and vision care division. ... Joseph Jimenez, chief executive officer of Novartis, said: “His expertise in
-
Novaliq GmbH appoints Friedrich von Bolen as chairman
Prior to his appointment as a board member of Novaliq, Dr Cagle was senior vice president of Alcon R&D and chief scientific officer from 1996 to mid-2008 having worked ... as a member of Alcon's research and development team for over thirty years.
More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Celltrion’s investigational mAb cuts COVID-19 recovery time
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- PHE study finds people who have had COVID-19 can still transmit the virus
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- EU proposes vaccine-sharing mechanism with low-income countries
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- WHO’s director-general deems vaccine nationalism a “catastrophic moral failure”
- Lilly partners with Merus on development of bispecific antibodies for cancer
- Medical research charities need our help – support is needed to continue funding life-saving research and improving lives
- Research Partnership appoints Hannah Osborn to MedTech director role
PMHub
Pegasus
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
